Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Clinical remission · Patients with active Crohn's disease

Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.36 [1.11, 1.66]
4 studies · 1485 participants
Moderate

Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate